Skip to main content

Advertisement

Table 4 Comparison of median and interquartile range of plasma efavirenz (EFV) concentrations (mg/L) between patients treated with EFV based HAART only (EFV only) versus TB-HIV coinfected patients treated with EFV based HAART plus RIF based TB therapy (EFV + RIF) stratified by observed neuropsychiatric symptoms during therapy (Yes) and who did not (No) during therapy

From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

  Neuropsychiatric disorders (No) Neuropsychiatric disorders (Yes)
  EFV only EFV + RIF EFV only   EFV + RIF
N Median (IQR) N Median (IQR) N Median (IQR) N Median (IQR)
Day-3 15 2.29 (1.41-2.88) 22 1.48 (1.15-1.88) 41 2.6 (2.09-2.94) 84 1.97 (1.38-2.91)
week-1 13 2.25 (1.84-2.69) 15 1.53 (1.28-1.97) 39 2.47 (2.09-3.23) 41 1.9 (1.34-2.61)
week-2 15 1.9 (1.27-2.3) 25 1.66 (1.36-2.11) 37 2.51 (1.84-3.43) 74 2.05 (1.4-2.67)
week-4 12 1.64 (1.46-2.43) 28 1.57 (1.19-2.17) 36 2.65 (2.05-3.56) 74 2.37 (1.55-3.57)
week-6 12 2.11 (1.46-3.41) 24 1.77 (1.37-2.02) 25 2.43 (1.94-3.51) 61 2.17 (1.66-4.63)
week-8 14 1.69 (1.41-2.49) 31 1.56 (1.34-3.05) 35 2.48 (2.23-3.13) 86 1.91 (1.48-3.22)
week-12 12 1.86 (1.45-2.26) 29 1.84 (1.45-2.7) 31 2.61 (2.04-4.09) 70 2.29 (1.56-4.45)
  1. No significant difference in EFV concentrations between treatment groups was observed.